A Phase II Study of Surufatinib in People with Advanced Soft-Tissue Sarcomas

Share
Print

Full Title

A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Surufatinib (HMPL-012), Previously Named Sulfatinib in Advanced Solid Tumors

Purpose

People with soft-tissue sarcoma have shown promising responses to drugs called tyrosine kinase inhibitors (TKIs). TKIs target enzymes called tyrosine kinases that are located in or on the surface of cancer cells. But sometimes the cancer comes back or the treatment causes side effects,

This study will assess safety and effectiveness of the investigational TKI surufatinib in people with advanced soft-tissue sarcoma. Researchers think surufatinib may stop or slow the growth and development of blood vessels that cancer cells need to live and multiply, but with fewer bad side effects than other TKIs. Surufatinib is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable or metastatic soft-tissue sarcoma such as epithelioid sarcoma, angiosarcoma, pigmented villonodular synovitis, or synovial sarcoma that continues to grow despite prior treatment.
  • Patients should recover from the serious side effects of previous treatments before entering the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Sujana Movva at 646-888-6787.

Protocol

20-239

Phase

I/II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators